Advertisement

Folia Microbiologica

, 54:457 | Cite as

Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis — case report

  • S. LetkiewiczEmail author
  • R. Międzybrodzki
  • W. Fortuna
  • B. Weber-Dąbrowska
  • A. Górski
Article

Abstract

The treatment of three patients suffering from chronic bacterial prostatitis who were qualified for an experimental phage therapy protocol managed at the Phage Therapy Unit in Wrocław is described. They had previously been treated unsuccessfully with long-term targeted antibiotics, autovaccines, and laser biostimulation. Rectal application of phage lysates targeted against Enterococcus faecalis cultured from the prostatic fluid gave encouraging results regarding bacterial eradication, abatement of clinical symptoms of prostatitis, and lack of early disease recurrence.

Keywords

Prostatitis Enterococcus Faecalis Digital Rectal Examination Chronic Prostatitis Phage Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

CBP

chronic bacterial prostatitis

PFU

plaque-forming unit(s)

DRE

digital rectal examination

PSA

prostate-specific antigen

IIET

Institute of Immunology and Experimental Therapy

PT

phage therapy

NIH-CPSI

National Institutes of Health Chronic Prostatitis Symptom Index

Qmax

maximum urinary flow rate

TRUS

transrectal ultrasound (method)

References

  1. Arias C.A., Murray B.E.: Antibiotic-resistant bugs in the 21st century — a clinical super-challenge. New Engl.J.Med. 360, 439–443 (2009).CrossRefPubMedGoogle Scholar
  2. Benway B.M., Moon T.D.: Bacterial prostatitis. Urol.Clin.N.Am. 35, 23–32 (2008).CrossRefGoogle Scholar
  3. Biswas B., Adhya S., Washart P., Paul B., Trostel A.N., Powell B., Carlton R., Merril C.R.: Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect.Immun. 70, 204–210 (2002).CrossRefPubMedGoogle Scholar
  4. Drahovská H., Slobodníková L., Kocíncová D., Seman M., Končeková R., Trupl J., Turňa J.: Antibiotic resistance and virulence factors among clinical and food enterococci isolated in Slovakia. Folia Microbiol. 49, 763–768 (2004).CrossRefGoogle Scholar
  5. Dworniczek E., Kuzko K., Mróz E., Wojciech Ł., Adamski R., Sobieszczańska B., Seniuk A.: Virulence factors and in vitro adherence of Enterococcus strains to urinary catheters. Folia Microbiol. 48, 671–678 (2003).CrossRefGoogle Scholar
  6. Freitag T., Squires R.A., Schmid J.: Naturally occurring bacteriophages lyse a large proportion of canine and feline uropathogenic Escherichia coli isolates in vitro. Res.Vet.Sci. 85, 1–7 (2008).CrossRefPubMedGoogle Scholar
  7. Górski A., Międzybrodzki R., Borysowski J., Weber-Dąbrowska B., Lobocka M., Fortuna W., Letkiewicz S., Zimecki M., Filby G.: Bacteriophage therapy for the treatment of infections. Curr.Opin.Investig.Drugs 10, 766–774 (2009).PubMedGoogle Scholar
  8. Hoffmann M.: Tierversuche zur Schleimhautpassage und Resorptionsviramie von T3-Phagen nach oraler, trachealer und rektaler Gabe. Z.Bakteriol.Med.-Hyg.Bakteriol.Virusforsch.Parasitol. 198, 371–390 (1965).Google Scholar
  9. Hu W.L., Zhong S.Z., He H.X.: Treatment of chronic bacterial prostatitis with amikacin through anal submucosal injection. Asian J.Androl. 4, 163–167 (2002).PubMedGoogle Scholar
  10. Kurzępa A., Dąbrowska K., Świtała-Jeleń A., Górski A.: Molecular modification of T4 bacteriophage proteins and its potential application. Folia Microbiol. 54, 5–15 (2009).CrossRefGoogle Scholar
  11. Lang L.H.: FDA approves use of bacteriophages to be added to meat and poultry products. Gastroenterology 131, 1370 (2006).PubMedGoogle Scholar
  12. Litwin M.S., Mcnaughton-Collins M., Fowler F.J. Jr., Nickel J.C., Calhoun E.A., Pontari M.A., Alexander R.B., Farrar J.T., O’Leary M.P.: The National Institutes of Health Chronic Prostatitis Symptom Index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J.Urol. 162, 369–375 (1999).CrossRefPubMedGoogle Scholar
  13. Międzybrodzki R., Świtała-Jeleń K., Fortuna W., Weber-Dąbrowska B., Przerwa A., Kurzępa A., Łusiak-Szelachowska M., Dąbrowska K., Boratyński J., Syper D., Ługowski C., Poźniak G., Górski A.: Bacteriophage inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. Virus Res. 131, 233–242 (2008).CrossRefPubMedGoogle Scholar
  14. Międzybrodzki R., Fortuna W., Weber-Dąbrowska B., Górski A.: A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin.Exp.Med. (2009); doi: 10.1007/s10238-009-0044-2. Google Scholar
  15. VAN NIEUWKOOP C., VISSER L.G., GROENEVELD J.H., KUIJPER E.J.: Chronic bacterial prostatitis and relapsing Enterococcus faecalis bacteremia successfully treated with moxifloxacin. J.Infect. 56, 155–156 (2008).CrossRefPubMedGoogle Scholar
  16. Nigutová K., Štyriak I., Javorský P., Pristaš P.: Partial characterization of Enterococcus faecalis bacteriophage F4. Folia Microbiol. 53, 234–236 (2008).CrossRefGoogle Scholar
  17. Nishikawa H., Yasuda M., Uchiyama J., Rashel M., Maeda Y., Takemura I., Sugihara S., Ujihara T., Shimizu Y., Shuin T., Matsuzaki S.: T-Even-related bacteriophages as candidates for treatment of Escherichia coli urinary tract infections. Arch. Virol. 153, 507–515 (2008).CrossRefPubMedGoogle Scholar
  18. OmniLytics: AgriPhage™ product info; http://www.omnilytics.com/products/agriphage/agriphage_info/agriphage_over view.html (accessed 22.5.2009).
  19. Pronk M.J., Pelger R.C., Baranski A.G., van Dam A., Arend S.M.: Cure of chronic prostatitis presumably due to Enterococcus spp. and Gram-negative bacteria. Eur.J.Clin.Microbiol.Infect.Dis. 25, 270–271 (2006).CrossRefPubMedGoogle Scholar
  20. Schaeffer A.J.: Epidemiology and demographics of prostatitis. Eur.Urol. 2(Suppl.), 5–10 (2003).Google Scholar
  21. Schlegel P.N., Chang T.S., Marshall F.F.: Antibiotics: potential hazards to male fertility. Fertil.Steril. 55, 235–242 (1991).PubMedGoogle Scholar
  22. Shafik A., Mohi-El-Din M.: A new concept of the anatomy of the anal sphincter mechanism and the physiology of defecation — XXIV. Hemorrhoidal venous plexuses: anatomy and role in hemorrhoids. Coloproctology 7, 291–296 (1985).Google Scholar
  23. Ślopek S., Durlakowa I., Weber-Dąbrowska B., Kucharewicz-Krukowska A., Dąbrowski M., Bisikiewicz R.: Results of bacteriophage treatment of suppurative bacterial infections — I. General evaluation of the results. Arch.Immunol.Ther.Exp. 31, 267–291 (1983).Google Scholar
  24. Wagenlehner F.M.E., Diemer T., Naber K.G., Weidner W.: Chronic bacterial prostatitis (NIH type II): diagnosis, therapy and influence on the fertility status. Andrologia 40, 100–104 (2008).CrossRefPubMedGoogle Scholar
  25. Zhou J.F., Xiao W.Q., Zheng Y.C., Dong J., Zhang S.M.: Increased oxidative stress and oxidative damage associated with chronic bacterial prostatitis. Asian J.Androl. 8, 317–323 (2006).CrossRefPubMedGoogle Scholar

Copyright information

© Institute of Microbiology, v.v.i, Academy of Sciences of the Czech Republic 2009

Authors and Affiliations

  • S. Letkiewicz
    • 1
    • 2
    • 3
    • 4
    Email author
  • R. Międzybrodzki
    • 2
    • 3
  • W. Fortuna
    • 2
    • 3
  • B. Weber-Dąbrowska
    • 2
    • 3
  • A. Górski
    • 2
    • 3
  1. 1.Urological and Andrological Clinic UROGENTarnowskie GóryPoland
  2. 2.Bacteriophage Laboratory, Ludwik Hirszfeld Institute of Immunology and Experimental TherapyPolish Academy of SciencesWrocławPoland
  3. 3.Phage Therapy Unit, Healthcare Center, Institute of Immunology and Experimental TherapyPolish Academy of SciencesWrocławPoland
  4. 4.Phage Therapy Unit, Ludwik Hirszfeld Institute of Immunology and Experimental TherapyPolish Academy of SciencesWrocławPoland

Personalised recommendations